Shin Nippon Biomedical Laboratories, Ltd.

DB:YB3 Stock Report

Market Cap: €428.9m

Shin Nippon Biomedical Laboratories Valuation

Is YB3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of YB3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: YB3 (€10.2) is trading above our estimate of fair value (€1.7)

Significantly Below Fair Value: YB3 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YB3?

Key metric: As YB3 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for YB3. This is calculated by dividing YB3's market cap by their current earnings.
What is YB3's PE Ratio?
PE Ratio18.1x
EarningsJP¥3.90b
Market CapJP¥70.61b

Price to Earnings Ratio vs Peers

How does YB3's PE Ratio compare to its peers?

The above table shows the PE ratio for YB3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average64.2x
GXI Gerresheimer
21.5x21.8%€2.5b
1SXP SCHOTT Pharma KGaA
25.1x15.7%€3.8b
SRT3 Sartorius
194.8x35.2%€13.7b
PSG PharmaSGP Holding
15.6x13.6%€292.6m
YB3 Shin Nippon Biomedical Laboratories
18.1x14.4%€70.6b

Price-To-Earnings vs Peers: YB3 is good value based on its Price-To-Earnings Ratio (18.1x) compared to the peer average (64.2x).

Price to Earnings Ratio vs Industry

How does YB3's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
YB3 18.1xIndustry Avg. 37.3xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: YB3 is good value based on its Price-To-Earnings Ratio (18.1x) compared to the European Life Sciences industry average (37.5x).

Price to Earnings Ratio vs Fair Ratio

What is YB3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YB3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.1x
Fair PE Ratio13.4x

Price-To-Earnings vs Fair Ratio: YB3 is expensive based on its Price-To-Earnings Ratio (18.1x) compared to the estimated Fair Price-To-Earnings Ratio (13.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst YB3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€10.20
€15.51
+52.0%
42.3%€22.07€8.95n/a2
Oct ’25€7.50
€8.53
+13.8%
11.9%€9.55€7.51n/a2
Sep ’25€7.45
€8.47
+13.7%
11.9%€9.48€7.46n/a2
Aug ’25€7.40
€8.94
+20.8%
3.4%€9.25€8.63n/a2
May ’25€8.95
€19.25
+115.1%
11.1%€21.39€17.11n/a2
Apr ’25€9.10
€19.25
+111.5%
11.1%€21.39€17.11n/a2
Mar ’25€9.65
€22.80
+136.2%
23.3%€28.11€17.49n/a2
Feb ’25€10.50
€22.68
+116.0%
23.3%€27.97€17.40n/a2
Jan ’25€10.50
€22.68
+116.0%
23.3%€27.97€17.40n/a2
Dec ’24€9.85
€22.68
+130.3%
23.3%€27.97€17.40€9.852
Nov ’24€10.30
€23.40
+127.2%
23.3%€28.85€17.95€7.202
Oct ’24€11.60
€23.40
+101.7%
23.3%€28.85€17.95€7.502
Sep ’24€13.70
€23.40
+70.8%
23.3%€28.85€17.95€7.452
Aug ’24€13.10
€23.32
+78.0%
23.3%€28.76€17.89€7.402
Jul ’24€13.20
€23.32
+76.7%
23.3%€28.76€17.89€7.902
Jun ’24€15.60
€24.54
+57.3%
18.9%€29.84€18.57€7.803
May ’24€16.20
€24.50
+51.2%
26.2%€30.63€15.65€8.953
Apr ’24€18.40
€30.57
+66.2%
13.6%€34.74€26.40€9.102
Mar ’24€18.60
€30.57
+64.4%
13.6%€34.74€26.40€9.652
Feb ’24€15.00
€29.68
+97.8%
9.5%€32.50€26.85€10.502
Jan ’24€15.60
€28.95
+85.6%
9.5%€31.71€26.19€10.502
Dec ’23€18.50
€28.92
+56.3%
9.5%€31.67€26.17€9.852

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 21:50
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shin Nippon Biomedical Laboratories, Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuki TsukamotoBofA Global Research
Akitada IwasaDaiwa Securities Co. Ltd.
Masao YoshidaIchiyoshi Research Institute Inc.